Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
751 Hydrochlorothiazide 25mg Tablet C03AA03-000-T10-01-XX B Diuretic, hypertension None ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily
752 Hydrochlorothiazide 50mg Tablet C03AA03-000-T10-02-XX B Diuretic, hypertension None ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily
753 Hydrocortisone 1% & Neomycin 0.5% Cream D07CA01-952-G10-01-XXX B Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses None Apply sparingly to the affected area.
Adult: 3-4 times daily.
Children: 1-2 times daily
754 Hydrocortisone 1% Cream D07AA02-000-G10-01-XXX B Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses None Apply sparingly to the affected area.
Adult: 3-4 times daily.
Children: 1-2 times daily
755 Hydrocortisone 1% Ointment D07AA02-000-G50-01-XX B Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses None Apply sparingly to the affected area.
Adult: 3-4 times daily.
Children: 1-2 times daily
756 Hydrocortisone 10mg Tablet H02AB09-000-T10-01-XXX B i) Glucocorticoid replacement therapy in primary or secondary adrenal insufficiencies
ii) Congenital adrenal hyperplasia in children		 None ADULT: 20 - 30 mg daily in divided doses.
CHILD: 10-15mg/m2/day in 3 divided dose

The dosing is individualized according to product insert / protocol
757 Hydrocortisone Sodium Succinate 100mg Injection H02AB09-520-P40-01-XXX C Conditions responsive to systemic or local glucocorticoid injection therapy. None ADULT:
Initially 100 - 500 mg IV over 30 seconds to more than 10 minutes. Dose may be repeated at intervals of 2, 4 or 6 hours

CHILD: 2-4mg/kg/dose every 6 hourly.

The dosing is individualized according to product insert / protocol
758 Hydrogen Peroxide 20 volume Solution D08AX01241L9901XX C Skin disinfection, particularly cleansing and deodorising wounds and ulcers Hydrogen Peroxide 6% (=approx. 20 vol) shall be dispensed. For cleansing wounds: 1.5% to 6% solution apply 2-3 times daily or when necessary. As a mouthwash: rinse the mouth for 2-3 minutes with 15ml of hydrogen peroxide 6% diluted in half a tumblerful of warm water 2-3 times daily. Disinfecting cleaned equipment: immersion for 30 minutes in 6% solution. As ear drop for removal of wax: hydrogen peroxide 6% diluted with 3 parts of water preferably just before use
759 Hydroxychloroquine Sulphate 200 mg Tablet P01BA02-183-T10-01-XXX A i) SLE and mixed connective tissue disease for skin, joint and serosa
ii) Second line therapy for acute rheumatoid arthritis		 None i) Initially 400 mg daily in divided dose. Maintenance : 200 - 400 mg daily
ii) ADULT : 400 - 600 mg daily. Maintenance: 200 - 400 mg daily.
CHILD : up to 6.5 mg/kg daily (maximum 400mg daily)
760 Hydroxyethyl Cellulose Jelly V07AY00250G4001XX B For lubricating purpose Apply sufficiently for lubricating purpose
761 Hydroxyethyl Starch 6% Injection B05AA07000P9901XX B Therapy and prophylaxis of hypovolaemia and shock in connection with surgery trauma, infections and burns ADULT daily dose up to 20 ml/kg/day. Normally 500-1500 ml. The rate of infusion may approach 20 ml/kg/hour in acute haemorrhagic shock, slower rates in burns and septic shock. CHILD under 10 years do not exceed 15 ml /kg/hour.
762 Hydroxyprogesterone Caproate 250mg/ml Injection G03DA03-128-P20-01-XXX A Habitual abortion None IM: 250-500mg weekly as soon as pregnancy has been confirmed by diagnosis.
763 Hydroxyurea 500 mg Capsule L01XX05-000-C10-01-XXX A i)Solid tumours
ii) Chronic myelocytic leukaemia and myeloproliferative disease		 - i) Intermittent therapy: 80 mg/kg orally as a single dose every 3rd day.
Continuous therapy: 20 - 30 mg/kg orally as a single dose dly.
Concomitant therapy with irradiation: 80 mg/kg orally as a single dose every 3rd day (administration of hydroxyurea should be started at least 7 days before initiation of irradiation and continued during radiotherapy as well).

ii) Continuous therapy 20 - 30 mg/kg orally as a single dose daily
764 Hydroxyzine HCl 25mg Tablet N05BB01110T1001XX A Allergic pruritus Initially 25 mg at night, increased if necessary up to 25 mg 3-4 times daily. ADULT and CHILD more than 10 years : 50 - 75 mg; 6 - 10 years: 25 - 50 mg; 2 - 5 years: 12.5 - 25 mg; to be taken daily in divided doses
765 Hyoscine N-Butylbromide 10mg Tablet A03BB01-320-T10-01-XXX C Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system. Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only.
 ADULT 10-20mg, 3-4 times a day. CHILD 6-12 years old: 10mg 3 times a day.
766 Hyoscine N-Butylbromide 1mg/ml Liquid A03BB01-320-L50-01-XX B Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system None ADULT 10-20mg, 3-4 times a day. CHILD 6-12 years old: 10mg 3 times a day.
767 Hyoscine N-Butylbromide 20mg/ml Injection A03BB01-320-P30-01-XXX B Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system None ADULT: 20 mg IM/IV repeated after 30 min if needed. Max: 100 mg daily.
Not recommended for CHILD below 12 years.

Dosing is individualised and according to product insert/protocol
768 Ibandronic Acid 150mg Tablet M05BA06000T1003XX A* Treatment of postmenopausal osteoporosis to reduce the risk of fracture. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk. 150 mg once monthly
769 Ibuprofen 100mg/5ml Suspension M01AE01-000-L80-01-XXX B i. Anti-inflammatory for rheumatic disease
ii. Analgesic for treatment of mild to moderate pain		 Not indicated in fever due to infection Children: 5 - 10 mg/kg/dose (max 2.4 gm/day) every 6-8 hourly. Not recommended for <7kg
770 Ibuprofen 200 mg Tablet M01AE01000T1001XX B Pain and inflammation in rheumatic disease None Dosage: ADULT : 200 - 400 mg 3 times daily after food, maximum 3.2 g daily. CHILD : 30-50 mg/kg body weight daily in divided doses, maximum 2.4g daily. Lowest effective dose for the shortest possible duration.
771 Idarubicin 1mg/mL Injection L01DB06110P4002XX A* i) Acute non-lymphocytic leukemia (ANLL) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients.
ii) Acute lymphocytic leukemia (ALL) as second line treatment in adult and children.		 i) Adult: 12mg/m2 IV daily for 3 days in combination with cytarabine. Idarubicin may also be administered as a single agent and in combination, at a dose of 8mg/m2 IV daily for 5 days.
ii) Adult: 12mg/m2 IV daily for 3 days as a single agent. Children: 10mg/m2 IV daily for 3 days as a single agent. All of these dosages should take into account the hematological status of the patient and the dosages of other cytotoxic drugs when used in combination.
772 Idarucizumab 50 mg/ml solution for injection/infusion V03AB37-000-P30-01-XXX A* Idarucizumab is a specific reversal agent for dabigatran and is indicated in patients treated with dabigatran when rapid reversal of the anticoagulant effects of dabigatran is required:
i. For emergency surgery/urgent procedures
ii. In life-threatening or uncontrolled bleeding		 To be prescribed by cardiologist, haematologist, general medicine physician, anaesthesiologist and emergency physician only The recommended dose of Idarucizumab is 5 g (2 x 2.5 g/50 ml) to be administered intravenously, as two consecutive infusions over 5 to 10 minutes each or as a bolus injection.
773 Idursulfase 2mg/ml Injection A16AB09000P3001XX A* Hunter syndrome (Mucopolysaccharidosis II, MPS II). 0.5 mg/kg of body weight administered every week as an intravenous infusion.
774 Ifosfamide 1 g Injection L01AA06000P4001XX A* i) Solid tumours
ii) Leukaemia
iii) Lymphoma		 i) 1.2 - 2.4 g/m2/day for 3 - 7 days as a 30 - 120 minutes infusion. Alternatively, can also be given as a single high dose, eg. 5 g/m2 in a 24 hour infusion. Cycles may be repeated every 3 - 4 weeks
ii) CHILD: 400 - 3000 mg/m2/day for 3 - 5 days according to protocol
iii) Refer to protocols
775 Imatinib Mesylate 100mg Tablet L01XE01-196-T10-01-XXX A* i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy
ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kit		 i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day

ii) ADULT : 400mg/day
776 Imatinib Mesylate 400mg Tablet L01XE01-196-T10-02-XXX A* i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy
ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kit		 i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day

ii) ADULT : 400mg/day
777 Imiglucerase 400IU Injection A16AB02000P4002XX A* Non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: - anemia, after exclusion of other causes, such as iron deficiency - thrombocytopenia - bone disease, after exclusion of other causes, such as Vitamin D deficiency - hepatomegaly or splenomegaly Dosage should be individualized to each patient. Initial dosages range from 2.5 units/kg of body weight 3 times a week to 60 units/kg once every 2 weeks. Administered by intravenous infusion over 1-2 hours.
778 Imipenem 500mg and Cilastatin 500mg Injection J01DH51-961-P40-02-XXX A* Severe infections caused by susceptible pathogens especially useful in infections involving ESBL organisms. Not to be used for prophylaxis None Based on type or severity of infection, susceptibility of pathogen(s) and patient condition including body weight and renal function. ADULT: 1 - 2 g/day in 3 - 4 divided doses. Maximum: 4 g/day or 50 mg/kg/day. Infusion rate: less than 500 mg dose: over 20 - 30 minutes, more than 500 mg: dose over 40 - 60 minutes. CHILDREN: ≥ 40kg body weight should receive adult doses. CHILDREN AND INFANTS: <40kg body weight should receive 15mg/kg at six hour intervals. The total daily dose should not exceed 2g.
779 Imiquimod 5 % w/w Cream D06BB10000G1001XX A* Treatment of external genital and perianal warts or condyloma acuminata in adults Apply to affected area at bedtime for 3 times a week for up to 16 weeks; leave on skin for 6-10 hours
780 Immunoglobulin Tetanus Human 250 Units/Vial Injection J06BB02000P3001XX B Passive immunization against tetanus Prophylaxis of tetanus: IM 250 units. Treatment of tetanus: IM 30 - 300 units/kg

Halaman-halaman